In summary, over the last 10 years probably the most impressive benefit has long been accomplished in HER2/neu-overexpressing MBC. Introduction of bevacizumab for a VEGF-directed qualified therapy continues to be an issue on debate. Several of the novel therapeutics to the breast cancer armamentarium resulted in prolongation of survival for people